SWOG clinical trial number
CTSU/A061402

Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy

Closed
Phase
Abbreviated Title
Solitary Plasmacytoma of Bone: Rando PIII for Adjuvant Tx + Zoledronic Acid vs. Zoledronic Acid after RT
Status Notes
This study is permanently closed to accrual effective 8/15/19.
Activated
12/23/2015
Closed
08/15/2019
Participants
CTSU

Research committees

Myeloma

Treatment

Dexamethasone Zoledronic Acid CC-5013 (Lenalidomide) Ixazomib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Therapy Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
8%
Open
Phase